Mesenchymal Stem Cell Transplantation for Osteoarthritis
Key facts
- Who runs it
- Yantai Yuhuangding Hospital
- Where
- China1 site in 1 countryChoose a country to see its sites
- Trial code
- Status
- Terminated
- People taking part
- 2 people enrolled
- Started
- 8 Jul 2019
- Ended
- 28 Dec 2023
- Type of study
- Interventional, 2 groupsOne group gets an existing treatment, for comparison.
- Treatments tested
- Auotologous BMSCs plus autologous PRP
- Auotologous PRP
- Record updated
- 24 January 2024
- Why it stopped
- Due to government regulation
Who can take part
- Age
- 40 years to 70 years
- Sex
- Women and men
- Healthy volunteers
- Cannot take part
The registry criteria, word for word
Show all 15 criteriaShow less
Who can take part
- Subject has Kellgren and Lawrence grade II-IV primary osteoarthritis as determined by X-ray
- Subject's pain score is 8-13 points (Lequesne's index)
- Ages between 40-70 years
- Signed informed consent from the subject.-
Who cannot take part
- Subject not suitable for bone marrow suction surgery
- Subject's studied knee treated with intra-articular injection therapy within 6 months prior to screen
- Subject has undergone surgery on studied knee, including fracture surgery, arthroscopic surgery, meniscus repair surgery, or cruciate ligament reconstruction surgery
- Subject enrolled in any other cell therapy studies within the past 30 days
- Subject infected with hepatitis B, hepatitis C, HIV, syphilis or HTLV
- Subject with hypersensitivity/allergy to anesthetic
- Subject has a history of gouty arthritis, septic arthritis, rheumatoid arthritis and any other autoimmune arthritis of the knee joint
- Subject has had major medical problems in vital organs, such as; heart, liver, kidney, or lung.-
- Subject's creatinine values higher than 1.6mg/dl
- Subject with body mass index, BMI over 30
- Subject who the investigator considers inappropriate for the clinical trial due to any other reasons than those listed above
Where is this trial?
It has sites in one country. Choose a country to see its sites.
About the trial
What the trial wants to find out
The purpose of this study is to explore the efficacy and safety of autologous bone marrow-derived mesenchymal stem cells (BMSCs) plus autologous platelet rich plasma (PRP) in the treatment of severe knee osteoarthritis.
The 2 groups in the trial
- BMSCs plus PRP groupTreatment being tested
Three intra-articular injections in total and autologous bone marrow-derived mesenchymal stem cells (BMSCs) suspended in 3 ml autologous platelet rich plasma (PRP) for each injection. Time-points for intervention: 1) initial injection; 2) 3 months following initial injection; 3) 6 months following initial injection.
Treatment: Auotologous BMSCs plus autologous PRP
- PRP groupExisting treatment, for comparison
Three intra-articular injections in total and 3 ml autologous platelet rich plasma (PRP) for each injection. Time-points for intervention: 1) initial injection; 2) 3 months following initial injection; 3) 6 months following initial injection.
Treatment: Auotologous PRP
Data and sources
- Registry record
- Listed on ClinicalTrials.gov.How to verify a trial in the registry
- Official title
- Autologous Mesenchymal Stem Cell Transplantation for the Treatment of Knee Osteoarthritis
- Record updated
- 24 January 2024